CSIMarket Company Name, Ticker, Suppliers, else..
 
Barinthus Biotherapeutics Plc  (NASDAQ: BRNS)
 
Price: $0.7400 $0.00 0.000%
Day's High: $0.7400000095367432 Week Perf: 2.92 %
Day's Low: $ 0.74 30 Day Perf: 32.02 %
Volume (M): 0 52 Wk High: $ 1.83
Volume (M$): $ 0 52 Wk Avg: $0.76
Open: $0.74 52 Wk Low: $0.51



 Market Capitalization (Millions $) 30
 Shares Outstanding (Millions) 41
 Employees 14
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -42
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company owns and has filed trademarks for BARINTHUS, SNAP-TI, SNAP-CI, VACCITECH, SNAPVAX, and SYNTHOLYTIC, including trademarks acquired from Avidea Technologies, Inc. It uses its website and social media accounts to distribute material information and fulfill disclosure obligations. The company engages in product development, clinical trials, regulatory filings and approvals, collaborations, intellectual property protection, manufacturing, commercialization, and marketing of its product candidates.


   Company Address: 20400 Century Blvd Germantown 20874 MD
   Company Phone Number: 917-0966   Stock Exchange / Ticker: NASDAQ BRNS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
INO   -8.09%    
• View Complete Report
   



Management Announcement

Barinthus Biotherapeutics Shifts Strategic Focus to Immunology and Inflammation Amidst Financial Challenges and Leadership Change,

Published Fri, Jan 10 2025 1:00 PM UTC

Strategic Shift and Financial Challenges: Barinthus Bio s Journey in Immunology and InflammationIn the rapidly evolving landscape of biopharmaceuticals, Barinthus Biotherapeutics plc, based in Oxford, UK, has recently communicated a significant strategic pivot towards immunology and inflammation (I&I). This decision comes at a time when the company is navigating a challengin...
Management Changes

Barinthus Bios New CSO, Geoffrey Lynn, Faces Uphill Battle: Can Breakthroughs in Hepatitis B Resuscitate a Biotech Struggling with Losses,

Published Mon, Nov 25 2024 9:01 PM UTC

Barinthus Biotherapeutics Promotes Lynn Amid Financial Struggles: A Potential Rebirth in Hepatitis B Treatment?An Look into Barinthus Biotherapeutics and the Future of Hepatitis B TreatmentIn a surprising turn of events, Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company headquartered in Oxford, UK, has recently announced the promotion of Geoffrey Lyn...
Clinical Study

Breaking Boundaries in Hepatitis B Barinthus Bios Vanguard Victory in Phase 2b Trials,

Published Fri, Nov 15 2024 4:02 PM UTC

Breakthroughs in Chronic Hepatitis B Treatment: Barinthus Bio s Promising Phase 2b Trial Results Chronic Hepatitis B (CHB) continues to be a major global health challenge, with millions affected worldwide. New therapeutic approaches are urgently needed to combat the disease and Barinthus Bio is at the forefront with promising results from its ongoing clinical trials. This a...
Clinical Study

Barinthus Bio Breaks New Ground in Hepatitis B and Prostate Cancer Trials A Potential Paradigm Shift in Biotherapeutics

Published Tue, Oct 1 2024 12:00 PM UTC

In recent developments, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a pioneering clinical-stage biopharmaceutical firm, has made significant strides in its clinical programs targeting chronic hepatitis B (CHB) and prostate cancer. Notably, the completion of enrollment for two critical clinical trials the Phase 2b HBV003 trial for chronic hepatitis B and the Phase 1 PCA001...
Clinical Study

Barinthus Bios Breakthrough Hepatitis B Immunotherapy Shines at EASL Congress 2024

Published Wed, Jun 12 2024 8:01 PM UTC

Barinthus Bio Prioritizes Strategic Pipeline and Presents Positive Data for Hepatitis B Immunotherapeutic Candidate at EASL Congress 2024OXFORD, United Kingdom, May 22, 2024 - Barinthus Biotherapeutics plc (NASDAQ: BRNS), a leading biopharmaceutical company focused on developing innovative T cell immunotherapeutic candidates to combat chronic infectious diseases, autoimmunit...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 6,045.64
Price to Sales (Expected) -
Price to Book 0.53
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.19
Working Capital Ratio 5.54
Leverage Ratio (MRQ) 0.43
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.03 $
Revenues (TTM) 0 $
Cash Flow (TTM) -
Cash 1.45 $
Book Value 1.4 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 357
Net Income per Employee (TTM) -2,986,214
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -220380 %
Net Margin (MRQ) -211980 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.